Basit öğe kaydını göster

dc.contributor.authorÇelik, Önder
dc.contributor.authorErşahin, Aynur
dc.contributor.authorAcet, Mustafa
dc.contributor.authorÇelik, Nilüfer
dc.contributor.authorBaykuş, Yakup
dc.contributor.authorDeniz, Rulin
dc.contributor.authorÖzerol, Elif
dc.contributor.authorÖzerol, İbrahim
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:55:57Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:55:57Z
dc.date.issued2016en_US
dc.identifier.citationÇelik, Ö., Erşahin, A., Acet, M., Çelik, N., Baykuş, Y., Deniz, R. ... Özerol, İ. (2016). Disulfiram, as a candidate NF-kappa B and proteasome inhibitor, prevents endometriotic implant growing in a rat model of endometriosis. European Review For Medical and Pharmacological Sciences, 20(20), 4380-4389.en_US
dc.identifier.issn1128-3602
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2492
dc.descriptionWOS: 000388238500028en_US
dc.descriptionPubMed ID: 27831632en_US
dc.description.abstractOBJECTIVE: Disulfiram (DSF) exerts its therapeutic effects through oxidative, proteasome, and nuclear factor kappa beta (NF-kappa B) pathways. The study was planned to test the impact of DSF on growing of endometriotic implants in rats with experimentally induced endometriosis. PATIENTS AND METHODS: Thirty rats were labeled as the control (n = 8), sham (n = 6), GnRH-agonist (n = 8) and the DSF (n = 8) groups. The rats in the group 3 exposed to single dose leuprolide acetate. The rats in group 4 were treated with DSF for 21 days. The serum activity of oxidant and antioxidant markers, total oxidant status (TOS), total antioxidant status (TAS), interleukin-1 beta, and tumor necrosis factora (TNF-alpha) were determined. Implants were processed for NF-kappa B, PCNA, and CD34 immunostaining. RESULTS: The serum concentration of malondialdehyde in the DSF group was significantly higher than those in other groups. The concentration of TAS, TNF-alpha, and interleukin-1 beta in the DSF group considerably decreased compared to control group. Following treatment with DSF while the percentage of Grade 1 and 2 implants increased the percentage of Grade 3 and 4 implants decreased. The implants disappeared totally in two cases in the DSF group and one case in the GnRH-agonist group. The mean H-Scores of implant NF-kappa B and PCNA in DSF treated animals were found to significantly lower than those of the control group. CONCLUSIONS: By decreasing NF-kappa B expression, angiogenesis, and cell proliferation DSF prevents the growth of endometriotic implants.en_US
dc.language.isoengen_US
dc.publisherVerduci Publisheren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEndometriosisen_US
dc.subjectDisulfiramen_US
dc.subjectNF-Kappa Ben_US
dc.subjectOxidative Stressen_US
dc.titleDisulfiram, as a candidate NF-kappa B and proteasome inhibitor, prevents endometriotic implant growing in a rat model of endometriosisen_US
dc.typearticleen_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalıen_US
dc.identifier.volume20en_US
dc.identifier.issue20en_US
dc.identifier.startpage4380en_US
dc.identifier.endpage4389en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.wosqualityQ2en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster